Seasonal Administration of Omalizumab in Patients With Uncontrolled Asthma and Sensitization to Olive Pollen.

dc.contributor.authorSerrano, P
dc.contributor.authorNavas, A
dc.contributor.authorRuiz-León, B
dc.contributor.authorHerrero, L
dc.contributor.authorRondón, C
dc.contributor.authorJurado, A
dc.contributor.authorMoreno-Aguilar, C
dc.contributor.funderMenarini
dc.date.accessioned2025-01-07T13:48:40Z
dc.date.available2025-01-07T13:48:40Z
dc.date.issued2020-10-25
dc.description.abstractSensitization to olive pollen leads to the development of asthma. In areas with high pollen counts, such as the southern Mediterranean, sensitization to Ole e 7 leads to more severe asthma. In Cordoba, olive and grasses are major sources of pollen, causing rhinoconjunctivitis and asthma during the spring season. Only olive pollen reaches extreme counts (>20 000 grains/m3/y). Allergen immunotherapy (AIT) is indicated when sensitization is clinically relevant and pharmacologic control of asthma is not satisfactory. When sensitization to Ole e 7 is single or predominant, AIT is associated with a higher incidence of adverse reactions. Moreover, poor control of minor allergens in most extracts constitutes an additional difficulty. Therefore, AIT could be inappropriate for patients predominantly sensitized to Ole e 7. Omalizumab has been widely used to treat severe perennial allergic asthma. However, few data are available on severe asthma due to pollen sensitization. The aim of this study was to analyze the results of a pilot seasonal treatment with omalizumab under conditions of daily clinical practice in patients with uncontrolled seasonal asthma, strong sensitization to minor olive allergens, and exposure to high pollen counts.
dc.description.sponsorshipThis paper was supported by an unrestricted grant from Menarini.
dc.description.version
dc.identifier.citationSerrano P, Navas A, Ruiz-León B, Herrero L, Rondón C, Jurado A, et al. Seasonal Administration of Omalizumab in Patients With Uncontrolled Asthma and Sensitization to Olive Pollen. J Investig Allergol Clin Immunol. 2021;31(5):436-438.
dc.identifier.doi10.18176/jiaci.0657
dc.identifier.issn1018-9068
dc.identifier.pmid33237024
dc.identifier.unpaywallURLhttp://www.jiaci.org/revistas/doi10.18176_jiaci.0657_material-suppl-tables.pdf
dc.identifier.urihttps://hdl.handle.net/10668/25877
dc.issue.number5
dc.journal.titleJournal of investigational allergology & clinical immunology
dc.journal.titleabbreviationJ Investig Allergol Clin Immunol
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.organizationSAS - Hospital Infanta Margarita
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.number436-438
dc.provenanceRealizada la curación de contenido 11/06/2025
dc.publisherJIACI
dc.pubmedtypeJournal Article
dc.relation.publisherversionhttps://www.jiaci.org/summary/vol31-issue5-num2351
dc.rights.accessRights© The Author(s) 2021
dc.subjectAsthma
dc.subjectOlive pollen
dc.subjectOmalizumab
dc.subjectSeasonal
dc.subject.decsAsma
dc.subject.decsPolen
dc.subject.decsAlérgenos
dc.subject.decsOmalizumab
dc.subject.decsDesensibilización Inmunológica
dc.subject.decsEstaciones del Año
dc.subject.meshAsthma
dc.subject.meshHumans
dc.subject.meshOlea
dc.subject.meshOmalizumab
dc.subject.meshPollen
dc.subject.meshSeasons
dc.titleSeasonal Administration of Omalizumab in Patients With Uncontrolled Asthma and Sensitization to Olive Pollen.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number31

Files